Harmatz, P., Yu, Z. - F., Giugliani, R., Schwartz, I. V. D., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Inherited Metabolic Disease, 33(1), 51 - 60.

Harmatz, P., Giugliani, R., Schwartz, I., Guffon, N., et al. (2006). Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-l. Journal of Pediatrics, 148(4), 533 - 533.e.

Swiedler, S. J., Beck, M., Bajbouj, M., Giugliani, R., et al. (2005). Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). American Journal of Medical Genetics, 134 A(2), 144 - 150.